A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars
Recruiting · Phase 3 · NCT07207369
Conditions: Acne Scars
At a glance
- Research payments reported, 2025
- $32,789
- U.S. investigators named
- 4
- Sites paid
- 4
- Planned or actual enrollment
- 395
About the trial
- Sponsor
- AbbVie
- Tested
- ELAPR002f Injectable Gel (device), Saline Control (device)
- Dates
- Started 2025-10-24; completion 2029-11
- Results posted
- Not yet
Atrophic acne scars are flat, indented or with an inverted center scars that develop at the endpoint of the normal healing process for acne. Acne scarring that remains after acne resolves has a significant impact on health related quality of life, including reduced self-esteem and embarrassment/self consciousness. ELAPR002f provides an immediate space-occupying effect for filling in the scar tissue. The purpose of this study is to assess how safe and effective ELAPR002f injectable gel is on adult participants with atrophic acne scars. ELAPR002f injectable gel is an investigational device being developed for the treatment of facial atrophic acne scars. There are 2 cohorts in this study. In…
From ClinicalTrials.gov, last updated 2025-11-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $32,789 in research payments for this study in 2025 (57 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- James F. Pehoushek, MD MPH Dermatology · Glendale, AZ
- Amir Moradi, MD ENT (Otolaryngology) · Vista, CA
- Katherine Z. Holcomb, M.D. Dermatology · Metairie, LA
- Rosalyn George, M.D. Dermatology · Wilmington, NC
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- H&h Research LLC $12,000
- Advanced Research Associates $6,000
- $5,821
- Wdc Cosmetic and Research PLLC $5,468
- Pacific Clinical Innovations Inc $3,500
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.